Literature DB >> 15136236

Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study.

Michael A Thompson, Robert A Kyle, L Joseph Melton, Matthew F Plevak, S Vincent Rajkumar.   

Abstract

Interleukin-6 (IL-6) and C-reactive protein (CRP, a surrogate marker for IL-6) are important in monoclonal gammopathy of undetermined significance (MGUS) and myeloma. Smoking and obesity may elevate CRP levels, while statins decrease CRP levels. A case-control study in 200 MGUS patients found that statin use, smoking history and obesity do not affect MGUS progression.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15136236

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  5 in total

1.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Authors:  Marta Chesi; Geoffrey M Matthews; Victoria M Garbitt; Stephen E Palmer; Jake Shortt; Marcus Lefebure; A Keith Stewart; Ricky W Johnstone; P Leif Bergsagel
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

2.  Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.

Authors:  Geffen Kleinstern; Dirk R Larson; Cristine Allmer; Aaron D Norman; Grace Muntifering; Jason Sinnwell; Alissa Visram; Vincent Rajkumar; Angela Dispenzieri; Robert A Kyle; Susan L Slager; Shaji Kumar; Celine M Vachon
Journal:  Blood Cancer J       Date:  2022-04-19       Impact factor: 9.812

3.  Body mass index, physical activity, and risk of multiple myeloma.

Authors:  Brenda M Birmann; Edward Giovannucci; Bernard Rosner; Kenneth C Anderson; Graham A Colditz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-07       Impact factor: 4.254

Review 4.  The skinny on obesity and plasma cell myeloma: a review of the literature.

Authors:  K R Carson; M L Bates; M H Tomasson
Journal:  Bone Marrow Transplant       Date:  2014-05-12       Impact factor: 5.483

5.  Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Vicky C Chang; Ali A Khan; Wen-Yi Huang; Hormuzd A Katki; Mark P Purdue; Ola Landgren; Jonathan N Hofmann
Journal:  Blood Cancer J       Date:  2022-04-01       Impact factor: 11.037
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.